SEC Form 4 · accession 0001209191-16-153908
Intra-Cellular Therapies, Inc. · ITCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Moshe Alafi
10% Owner
Period of report
Dec 6, 2016
Accepted (ET)
Dec 7, 2016 · 4:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 6, 2016 | P | 44,174 | $16.3319 | A | 3,674,379 | I | Held by Alafi Capital Company, LLC |
| Common StockF3,F2 | Dec 7, 2016 | P | 20,826 | $16.1355 | A | 3,695,205 | I | Held by Alafi Capital Company, LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.28 to $16.50 per share, inclusive.
- F2Mr. Alafi is a managing partner of Alafi Capital Company, LLC and may be deemed to beneficially own the shares held by Alafi Capital Company, LLC. Mr. Alafi disclaims beneficial ownership of the securities held by Alafi Capital Company, LLC except to the extent of his pecuniary interest therein.
- F3The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.91 to $16.37 per share, inclusive.